MEGGAN CHAPPELL: Open Payments
NPI 1003499609 · LONG BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,884 in 73 payments from 15 companies in 2025. Trend: 2023 $1,462 · 2024 $1,831 · 2025 $1,884
Food & beverage: $1,884
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 12 | $323 |
| GENZYME CORPORATION | 6 | $276 |
| Madrigal Pharmaceuticals | 9 | $264 |
| Aimmune Therapeutics, Inc. | 14 | $228 |
| PFIZER INC. | 7 | $191 |
| Phathom Pharmaceuticals, Inc. | 7 | $170 |
| Regeneron Healthcare Solutions, Inc. | 5 | $146 |
| ABBVIE INC. | 4 | $89 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
| Ardelyx, Inc. | 2 | $37 |
Products named: DUPIXENT, TREMFYA, REZDIFFRA, VOQUEZNA, VELSIPITY, VOWST, ZENPEP, CREON.
Industry payments across CA — which companies pay providers there.
